Authors: Sander S.van Berkela & Floris L.van Delftab Abstract Target-specific killing of tumor cells with antibody-drug conjugates (ADCs) is an elegant concept in the continued fight against cancer. However, despite more than 20 years of clinical development, only […]

Read More